Joe Henein is a senior executive with an accomplished multidisciplinary career of 40 years in the pharmaceutical industry, covering many geographies including USA (Global), Europe, and the Middle East/Africa. Joe holds a Pharm D Degree.
Joe joined as the operational founder of NewBridge as President and CEO- a specialty pharma start-up back in 2010 positioned to be first-in-class regional licensing and commercialization platform for innovative therapeutics. Headquartered in Dubai – UAE, NewBridge offers comprehensive pharmaceutical platform of services and expertise to Global Biopharma and Biotech Companies to bridge the access gap through licensing and commercialization of their U.S. FDA or EMA approved innovative therapeutics that address unmet medical needs of the Middle East and North Africa (MENA) region.
NewBridge is now the largest in its business model category across MENA, reputable and successful company that represents several blue-chip partners and blockbuster products in the region offering new therapeutic advancement to physicians, which helps improving patients’ journey.
Prior to that Joe worked in Big Pharma, mostly Wyeth Pharmaceuticals, now part of Pfizer. He assumed many roles of increased dimensions in the industry, most notably Vice President and Global Commercial Chair for number of therapeutic areas in Wyeth World Headquarters, like Infectious Diseases, and Women’s Health Care.
Joe also assumed the role of VP & Regional Managing Director for Wyeth in Middle East/Africa prior to joining NewBridge
Joe served on various Wyeth Executive Committees during his tenure as, Global R&D Council, Global Development Strategy Board, and European Operation Council.
On the industry level, he also served as the Vice Chair for the PhRMA MEA Committee and the Chair for the PhRMA MEA Ethics Review Board, under his leadership he chaired the committee that authored and published the first voluntary compliance code book, now in its fourth edition. He also formed and chaired the first Regional Pharma Ethics Review Board in MENA.